Filing Details

Accession Number:
0000899243-21-012695
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-18 21:39:24
Reporting Period:
2021-03-16
Accepted Time:
2021-03-18 21:39:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599901 Avidity Biosciences Inc. RNA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1181556 A Arthur Levin C/O Avidity Biosciences, Inc.
10975 N. Torrey Pines Road, Suite 150
La Jolla CA 92037
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-05 37,022 $0.00 273,872 No 5 G Indirect By family trust
Common Stock Acquisiton 2021-03-05 37,022 $0.00 37,022 No 5 G Indirect By charitable remainder trust
Common Stock Acquisiton 2021-03-16 2,625 $1.24 2,625 No 4 M Direct
Common Stock Acquisiton 2021-03-16 1,975 $0.53 4,600 No 4 M Direct
Common Stock Disposition 2021-03-16 4,600 $27.87 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Indirect By family trust
No 5 G Indirect By charitable remainder trust
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-03-16 2,625 $0.00 2,625 $1.24
Common Stock Stock Option (Right to Buy) Disposition 2021-03-16 1,975 $0.00 1,975 $0.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
208,483 2030-02-18 No 4 M Direct
45,430 2027-08-28 No 4 M Direct
Footnotes
  1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.8571 to $27.8739. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
  4. This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.